| Literature DB >> 35278135 |
Doke J M Buurman1,2, Anna C H Willemsen3,4,5, Caroline M Speksnijder6,7,8, Laura W J Baijens3,9, Ann Hoeben3,4, Frank J P Hoebers3,10, Peter Kessler6,3, Annemie M W J Schols5.
Abstract
PURPOSE: Prior to radiotherapy combined with chemotherapy (CRT) or biotherapy (BRT) for oropharyngeal squamous cell carcinoma (OPSCC), teeth with poor prognosis that pose a risk for post-RT osteoradionecrosis (ORN) are removed. The effect of tooth loss on body weight loss and tube feeding (TF) dependency during CRT/BRT is unknown. This study aimed to evaluate the effect of incomplete dentition, tooth extractions prior to CRT/BRT, and the subsequent loss of functional units on (1) weight loss during CRT/BRT and (2) the need for TF during CRT/BRT for OPSCC.Entities:
Keywords: Chemoradiotherapy; Dental focal infection; Oropharyngeal cancer; Tooth extraction; Tooth loss; Weight loss
Mesh:
Year: 2022 PMID: 35278135 PMCID: PMC9046292 DOI: 10.1007/s00520-022-06942-6
Source DB: PubMed Journal: Support Care Cancer ISSN: 0941-4355 Impact factor: 3.359
Terminology clarification
| Edentulous | No functional teeth in place |
| Functional tooth | A tooth was considered functional if it could make contact with an opposing (prosthetic) tooth. Roots or impacted teeth are considered as nonfunctional |
| Functional unit | Functional tooth, bridge pontic, or crown (on implants), which could make contact with an opposing (prosthetic) tooth, is considered a functional unit |
| Occlusal unit [ | A measure to represent the chewing surface of the postcanine functional unit. One pair of occluding premolars is equal to one occlusal unit. One pair of occluding molars is considered as two occlusal units. Third molars are excluded |
| Eichner index [ | A validated measure describing the existing posterior functional units in support zones. It is divided into 3 main classes |
| Eichner index A | Functional units exist in all 4 posterior support zones |
| Eichner index B | Functional units are present in one to three posterior support zones or within the anterior area only |
| Eichner index C | No functional units left |
Baseline characteristics
| > | |||
|---|---|---|---|
| Patient characteristics | |||
| Age (years) | |||
| Mean ± SD | 58.4 ± 9.5 | 59.4 ± 6.0 | |
| Median (IQR) | 60.0 (13) | 59.5 (9) | 0.971c |
| Male | 25 (68%) | 29 (73%) | 0.637d |
| Female | 12 (32%) | 11 (28%) | |
| Smoking history | 33 (89%) | 35 (88%) | 1.000a |
| No history of smoking | 4 (11%) | 5 (13%) | |
| Alcohol consumption | 19 (51%) | 27 (68%) | 0.149d |
| No alcohol consumption | 18 (49%) | 13 (33%) | |
| BMI at start RT ((kg/m2); mean ± SD | 24.5 ± 5.0 | 26.7 ± 4.2 | |
| Percentage weight loss prior to CRT/BRT; mean ± SD | 2.4 ± 3.7 | 1.7 ± 3.2 | 0.373b |
| Dysphagia (CTCAE grade) | |||
| 0—No symptoms of dysphagia | 18 (49%) | 15 (38%) | 0.077d |
| 1—Symptomatic, regular diet | 7 (19%) | 17 (43%) | |
| 2—Symptomatic, altered eating/swallowing | 12 (32%) | 8 (20%) | |
| WHO PS 0 | 9 (24%) | 14 (35%) | 0.325a |
| WHO PS 1 | 28 (76%) | 25 (63%) | |
| WHO PS 2 | 0 (0%) | 1 (3%) | |
| CCI 0 | 7 (19%) | 2 (5%) | 0.231a |
| CCI 1 | 7 (19%) | 12 (30%) | |
| CCI 2 | 10 (27%) | 17 (43%) | |
| CCI 3 | 7 (19%) | 4 (10%) | |
| CCI 4 | 2 (5%) | 3 (8%) | |
| CCI 5 | 1 (3%) | 1 (3%) | |
| CCI 6 | 3 (8%) | 1 (3%) | |
| Tumor characteristics | |||
| T1 | 5 (14%) | 7 (18%) | 0.287a |
| T2 | 8 (22%) | 12 (30%) | |
| T3 | 10 (27%) | 4 (10%) | |
| T4 | 14 (38%) | 17 (43%) | |
| N0 | 8 (22%) | 6 (15%) | 0.886a |
| N1 | 1 (3%) | 1 (3%) | |
| N2 | 27 (73%) | 32 (80%) | |
| N3 | 1 (3%) | 1 (3%) | |
| Stage II | 0 (0%) | 1 (3%) | 0.829 |
| Stage III | 3 (8%) | 2 (5%) | |
| Stage IV | 34 (92%) | 37 (93%) | |
| p16 + | 20 (54%) | 26 (65%) | 0.328d |
| p16- | 17 (46%) | 14 (35%) | |
| Dental status | |||
| Edentulous at start RT | 13 (35%) | 9 (23%) | 0.220d |
| Dentate at start RT | 24 (65%) | 31 (78%) | |
| Eichner index A at first assessment | 7 (19%) | 12 (30%) | 0.427d |
| Eichner index B at first assessment | 11 (30%) | 8 (20%) | |
| Eichner index C at first assessment | 19 (51%) | 20 (50%) | |
| Eichner index A at start RT | 4 (11%) | 8 (20%) | 0.547a |
| Eichner index B at start RT | 13 (35%) | 11 (28%) | |
| Eichner index C at start RT | 20 (54%) | 21 (53%) | |
| Decrease in Eichner index (ABC) due to tooth extractions prior to CRT/BRT | 4 (11%) | 5 (13%) | 1.000a |
| No decrease in Eichner index (ABC) due to tooth extractions prior to CRT/BRT | 33 (89%) | 35 (88%) | |
| OU at first assessment; mean ± SD | 3.5 ± 4.5 | 4.0 ± 4.7 | 0.642b |
| OU at start RT; mean ± SD | 2.1 ± 3.6 | 3.2 ± 4.4 | 0.249b |
| Loss of OU due to tooth extractions prior to CRT/BRT | |||
| Mean ± SD | 1.4 ± 2.3 | 0.8 ± 1.8 | |
| Median (IQR) | 0.0 (3) | 0.0 (1) | 0.317c |
| Tooth extractions prior to CRT/BRT | 20 (54%) | 31 (78%) | |
| No tooth extractions prior to CRT/BRT | 17 (46%) | 9 (23%) | |
| Tooth extractions and/or additional interventions | 23 (62%) | 32 (80%) | 0.083d |
| No tooth extractions and/or additional interventions | 14 (38%) | 8 (20%) | |
| Number of removed teeth; mean ± SD | 3.4 ± 5.0 | 4.8 ± 6.1 | 0.289b |
| Treatment characteristics | |||
| Primary CRT/BRT | 35 (95%) | 38 (95%) | 1.000a |
| Postoperative CRT | 2 (5%) | 2 (5%) | |
| Cisplatin | 27 (73%) | 29 (73%) | 0.963d |
| Cetuximab | 10 (27%) | 11 (28%) | |
| RT dose to contralateral submandibular gland (Gy); mean ± SD | 48.1 ± 12.0* | 49.7 ± 10.6* | 0.529b |
| RT dose to contralateral parotid salivary gland (Gy); mean ± SD | 24.2 ± 10.5 | 22.2 ± 7.1 | 0.345b |
| RT dose to superior PCM (Gy); mean ± SD | 59.3 ± 11.6 | 59.3 ± 7.5 | 0.995b |
| RT dose to middle PCM (Gy); mean ± SD | 59.8 ± 6.4 | 60.1 ± 7.1 | 0.870b |
| RT dose to inferior PCM (Gy); mean ± SD | 49.4 ± 10.8 | 49.5 ± 8.4 | 0.939b |
| RT dose to oral cavity (Gy); mean ± SD | 45.9 ± 11.0 | 45.2 ± 9.5 | 0.740b |
| RT dose to cricopharyngeal muscle (Gy); mean ± SD | 44.5 ± 7.3 | 43.3 ± 6.5 | 0.433b |
| RT dose to cervical esophagus (Gy) | |||
| Mean ± SD | 41.5 ± 8.3 | 37.0 ± 11.1 | |
| Median (IQR) | 42.0 (8.0) | 40.1 (17.7) | 0.129c |
| TF during CRT/BRT (any duration) | 24 (65%) | 23 (58%) | 0.508d |
| No TF | 13 (35%) | 17 (43%) | |
BMI body mass index, CCI Charlson comorbidity index, CRT/BRT chemoradiotherapy or bioradiotherapy, WHO PS World Health Organization performance status, p16 ± p16 positive/negative tumor as surrogate marker for human papilloma virus, PCM pharyngeal constrictor muscles, RT radiotherapy, TF tube feeding; TNM-classification, tumor (T), node (N), and metastasis (M) classification according to the 7th edition [34]
Bold values denote statistical significance at the p < 0.05 level
aFisher’s exact test
bIndependent T-test
cMann-Whitney U test
dChi2-test
*Two missing values due to a bilateral neck dissection
Univariable and multivariable analysis of factors potentially contributing to a significant weight loss of > 5% during CRT/BRT and to TF dependency
| Significant weight loss of > 5% during CRT/BRT | TF dependency | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariable analysis | Multivariable analysis* | Univariable analysis | Multivariable analysis* | |||||||||||||
| OR | CI-95% | OR | CI-95% | OR | CI-95% | OR | CI-95% | |||||||||
| Lower | Upper | Lower | Upper | Lower | Upper | Lower | Upper | |||||||||
| Age | 1.018 | 0.960 | 1.078 | 0.556 | 0.980 | 0.922 | 1.041 | 0.509 | ||||||||
| Sex (male vs. female) | 1.265 | 0.476 | 3.363 | 0.637 | 0.776 | 0.281 | 2.141 | 0.624 | ||||||||
| Smoking | 0.848 | 0.210 | 3.434 | 0.818 | 0.759 | 0.175 | 3.297 | 0.713 | ||||||||
| Alcohol | 1.968 | 0.781 | 4.956 | 0.151 | 0.982 | 0.386 | 2.501 | 0.970 | ||||||||
| BMI | 1.113 | 1.003 | 1.236 | 1.130 | 1.011 | 1.262 | 0.987 | 0.895 | 1.089 | 0.799 | ||||||
| Weight loss prior to CRT/BRT | 0.941 | 0.823 | 1.075 | 0.370 | 1.187 | 1.001 | 1.407 | |||||||||
| Dysphagia at start RT (CTCAE grade 2 vs. 0 or 1) | 0.521 | 0.185 | 1.468 | 0.217 | 1.256 | 0.435 | 3.627 | 0.673 | ||||||||
| WHO PS (1 or 2 vs. 0) | 0.597 | 0.221 | 1.611 | 0.309 | 1.689 | 0.627 | 4.547 | 0.300 | ||||||||
| CCI (≥ 4 vs. < 4) | 0.738 | 0.205 | 2.659 | 0.642 | 0.732 | 0.202 | 2.650 | 0.634 | ||||||||
| T3 or T4 vs. T0, T1 or T2 | 0.599 | 0.239 | 1.498 | 0.273 | 1.765 | 0.696 | 4.476 | 0.232 | ||||||||
| N2 or N3 vs. N0 or N1 | 1.821 | 0.578 | 5.739 | 0.306 | 1.056 | 0.333 | 3.342 | 0.927 | ||||||||
| p16 + vs. p16- | 1.579 | 0.631 | 3.948 | 0.329 | 0.487 | 0.185 | 1.283 | 0.145 | ||||||||
| Edentulous vs. dentate | 0.536 | 0.197 | 1.462 | 0.223 | 0.892 | 0.325 | 2.447 | 0.825 | ||||||||
| Decrease in Eichner Index (ABC) due to tooth extractions prior to CRT/BRT (binary) | 1.179 | 0.291 | 4.771 | 0.818 | 0.465 | 0.114 | 1.894 | 0.285 | ||||||||
| Tooth extractions (yes vs. no) | 2.928 | 1.094 | 7.834 | 3.360 | 1.185 | 9.529 | 0.756 | 0.283 | 2.019 | 0.577 | ||||||
| Tooth extractions and additional interventions (yes vs. no) | 2.435 | 0.877 | 6.756 | 0.087 | 0.484 | 0.165 | 1.425 | 0.188 | ||||||||
| Number of removed teeth | 1.047 | 0.961 | 1.140 | 0.291 | 0.995 | 0.917 | 1.080 | 0.909 | ||||||||
| Loss of OU due to tooth extractions prior to CRT/BRT | 0.867 | 0.687 | 1.095 | 0.232 | 1.125 | 0.877 | 1.445 | 0.354 | ||||||||
| Cetuximab vs. cisplatin (ref) | 1.024 | 0.375 | 2.795 | 0.963 | 0.355 | 0.127 | 0.995 | 0.226 | 0.070 | 0.731 | ||||||
| RT dose to contralateral parotid gland | 0.975 | 0.925 | 1.028 | 0.347 | 1.018 | 0.964 | 1.075 | 0.524 | ||||||||
| RT dose to contralateral submandibular gland | 1.013 | 0.973 | 1.056 | 0.523 | 1.048 | 1.001 | 1.096 | 1.067 | 1.013 | 1.124 | ||||||
| RT dose to superior PCM | 1.000 | 0.954 | 1.048 | 0.995 | 1.013 | 0.966 | 1.063 | 0.584 | ||||||||
| RT dose to median PCM | 1.006 | 0.941 | 1.075 | 0.868 | 1.040 | 0.970 | 1.115 | 0.272 | ||||||||
| RT dose to inferior PCM | 1.002 | 0.956 | 1.050 | 0.938 | 1.044 | 0.990 | 1.102 | 0.112 | ||||||||
| RT dose to oral cavity | 0.992 | 0.950 | 1.037 | 0.737 | 1.031 | 0.983 | 1.081 | 0.211 | ||||||||
| RT dose to cricopharyngeus muscle | 0.974 | 0.911 | 1.040 | 0.428 | 1.088 | 1.010 | 1.173 | |||||||||
| RT dose to cervical esophagus | 0.952 | 0.904 | 1.002 | 0.060 | 1.044 | 0.995 | 1.096 | 0.077 | ||||||||
| TF use | 0733 | 0.292 | 1.841 | 0.508 | ||||||||||||
BMI body mass index, CCI Charlson comorbidity index, CRT/BRT chemoradiotherapy or bioradiotherapy, WHO PS World Health Organization performance status, OU occlusal units, PCM pharyngeal constrictor muscles, RT radiotherapy, TF tube feeding
Boldface values denote statistical significance at the p < 0.05 level
*Step-backward analysis of all variables with p < 0.05 in univariable analysis